A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
Completed · Phase 3 · NCT03430843
Conditions: Esophageal Squamous Cell Carcinoma (ESCC)
At a glance
- Research payments reported, 2025
- $768,068
- U.S. investigators named
- 9
- Sites paid
- 9
- Planned or actual enrollment
- 512
About the trial
- Sponsor
- BeiGene
- Tested
- Tislelizumab (drug), Paclitaxel (drug), Docetaxel (drug), Irinotecan (drug)
- Dates
- Started 2018-01-26; completion 2022-12-28
- Results posted
- Yes
The purpose of this study was to evaluate the efficacy and safety of tislelizumab as second line treatment in participants with advanced unresectable/metastatic ESCC that had progressed during or after first line therapy.
From ClinicalTrials.gov, last updated 2024-10-26. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Beone Medicines Ltd. reported $768,068 in research payments for this study in 2025 (319 payments).
Products named: Tevimbra
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- David Berz, MD, PHD, MPH Hematology & Oncology · Los Angeles, CA
- Giribala R. Patel, M.D. Medical Oncology · Fullerton, CA
- Rama Balaraman, M.D. Medical Oncology · Ocala, FL
- Mark A. Socinski, MD Hematology & Oncology · Orlando, FL
- Firas B. Badin, M.D. Hematology & Oncology · Lexington, KY
- Elizabeth Ellent Hematology & Oncology · New Orleans, LA
- Yan Ji, M.D, PH.D. Hematology & Oncology · Saint Paul, MN
- Atul Kumar, MD, PHD Medical Oncology · Albuquerque, NM
- Ali I. Amjad, M.D. Hematology & Oncology · New Castle, PA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Adventhealth Orlando, FL $365,177
- Ocala Oncology Center Pl $173,656
- Valkyrie Clinical Trials, Inc $67,233
- Healthpartners Institute $55,734
- Allegheny Singer Research Institute $37,855
- Baptist Health Lexington, KY $30,587
- Providence Medical Foundation $23,957
- New Mexico Cancer Care Alliance $8,840
- University Medical Center New Orleans, LA $5,029
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.